What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9484-9497

  Leidinger, Petra ^a   Backes, Christina ^b   Dahmke, Indra N ^a   Galata, Valentina ^b   Huwer, Hanno ^c   Stehle, Ingo ^a   Bals, Robert ^a   Keller, Andreas ^b   Meese, Eckart ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Voelklingen Heart Centre   (Germany)

Author keywords

Cell separation; Leukocytes; Lung cancer; Microarray; microRNA

Indexed keywords

MICRORNA; MICRORNA 21; TUMOR MARKER;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; EXOSOME; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEUKOCYTE; LUNG CANCER; MALE; THROMBOCYTE; ADULT; BLOOD; CYTOLOGY; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; MONOCYTE; NATURAL KILLER CELL; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ADULT; B-LYMPHOCYTES; BIOMARKERS, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTES; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LEUKOCYTES; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES;

EID: 84910023965     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2419     Document Type: Article

References (41)

1. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34( Database issue):D140-144.
2. Kozomara A and Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39(Database issue):D152-157.
3. van Kouwenhove M, Kedde M and Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011; 11(9):644-656.
4. Kent OA and Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006; 25(46):6188-6196.
5. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-269.
6. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6:60.
7. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10(10):704-714.
8. Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C, Vogel B, Matzas M, Huwer H, Katus HA, Stahler C, Meder B and Meese E. Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Molecular bioSystems. 2011; 7(12):3187-3199.
9. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T and Ruprecht K. Toward the blood-borne miRNome of human diseases. Nature methods. 2011; 8(10):841-843. 10 Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP and Meese E. miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009; 9:353.
10. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP and Meese E. miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009; 9:353
11. Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P, Lenhof HP and Meese E. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 2011; 8(3):506-516.
12. Leidinger P, Keller A, Backes C, Huwer H and Meese E. MicroRNA expression changes after lung cancer resection: A follow-up study. RNA Biol. 2012; 9(6):900-910.
13. Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J, Lenhof HP and Meese E. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011; 74(1):41-47.
14. Leidinger P, Keller A and Meese E. MicroRNAs-Important Molecules in Lung Cancer Research. Front Genet. 2012; 2:104.
15. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
16. Allantaz F, Cheng DT, Bergauer T, Ravindran P, RossierMF, Ebeling M, Badi L, Reis B, Bitter H, D'AsaroM, Chiappe A, Sridhar S and Pacheco GD. Expressionm profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS One. 2012; 7(1):e29979.
17. Merkerova M, Belickova M and Bruchova H. Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol. 2008; 81(4):304-310.
18. Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, WhiteA, Kent D, Marmolejo L, Heuser M, Berg T, CopleyM, Ruschmann J, Sekulovic S and Benz C. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A. 2010; 107(35):15443-15448.
19. Matejuk A, Collet G, Nadim M, Grillon C and Kieda C. MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response. Arch Immunol Ther Exp (Warsz). 2013; 61(4):285-299.
20. Hochberg Y. A sharper bonferroni procedure for multiple tests of significance. Biometrica. 1988; 75:185-193.
21. Benjamini Y, Drai D, Elmer G, Kafkafi N and Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001; 125(1-2):279-284.
22. de Visser KE, Eichten A and Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6(1):24-37.
23. Kim R, Emi M and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007; 121(1):1-14.
24. Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C and Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012; 33(7):364-372.
25. Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?. Cancer Immunol Immunother. 2013.
26. Nishikawa H and Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127(4):759-767.
27. Gao W, Shen H, Liu L, Xu J and Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2010; 137(4):557-566.
28. Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013; 81(3):388-396.
29. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008; 54(10):1696-1704.
30. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T and ShuYQ. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011; 30(6): 407-414.
31. Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM and De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 2011; 104(7):847-851.
32. van Jaarsveld MT, Wouters MD, Boersma AW, Smid M, van Ijcken WF, Mathijssen RH, Hoeijmakers JH, Martens JW, van Laere S, Wiemer EA and Pothof J. DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. Molecular oncology. 2014; 8(3):458-468.
33. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, BowmanED and Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 2012; 130(6):1378-1386.
34. Bousquet M, Zhuang G, Meng C, Ying W, Cheruku PS, Shie AT, Wang S, Ge G, Wong P, Wang G, Safe S and Zhou B. miR-150 blocks MLL-AF9-associated leukemia through oncogene repression. Mol Cancer Res. 2013; 11(8):912-922.
35. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP and Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007; 131(1):146-159.
36. Zhang N, Wei X and Xu L. miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett. 2013; 587(15):2346-2351.
37. Sun Y, Su B, Zhang P, Xie H, Zheng H, Xu Y, Du Q, ZengH, Zhou X, Chen C and Gao W. Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. Oncol Rep. 2012; 29(2):704-712.
38. Watkins NA, Gusnanto A, de Bono B, De S, Miranda-Saavedra D, Hardie DL, Angenent WG, Attwood AP, Ellis PD, Erber W, Foad NS, Garner SF and IsackeCM. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood. 2009; 113(19):e1-9.
39. Dweep H, Sticht C, Pandey P and Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. Journal of biomedical informatics. 2011; 44(5):839-847.
40. Backes C, Keller A, Kuentzer J, Kneissl B, ComtesseN, Elnakady YA, Müller R, Meese E and Lenhof H-P. GeneTrail-advanced gene set enrichment analysis. Nucleic Acids Research. 2007; 35(Web Server issue).
41. Kanehisa M. The KEGG database. Novartis Found Symp. 2002; 247:91-101discussion 101-103, 119-128, 244-252.